Cebranopadol is the medication in play, and the German company Grünenthal has rights to its development.

In collaboration with the U.S. company Forest Labs, they performed a Phase IIa clinical trial on the use of a cebranopadol drug candidate called GRT6005, and the trial was completed in Jan. of 2012. The results were not published, however.

They terminated their development agreement with Forest Labs in Dec. of 2014, and right now are only showing an ongoing trial with cebranopadol for cancer pain.


http://www.grunenthal.com/grt-oceani.../265600020.jsp